OncoMatch/Clinical Trials/NCT05389293
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Is NCT05389293 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mosunetuzumab and Zanubrutinib for follicular lymphoma.
Treatment: Mosunetuzumab · Zanubrutinib — The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II BULKY (NONCONTIGUOUS), III, IV BULKY OR HIGH BURDEN DISEASE
Grade: 123A
Stage II bulky (noncontiguous), III, or IV bulky or high burden disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-lymphoma therapy
Prior anti-lymphoma therapy
Cannot have received: solid organ transplantation
Prior solid organ transplantation
Cannot have received: allogeneic stem cell transplantation
Exception: Previously transplanted patients must be off all GVHD-related prophylaxis in order to be considered eligible.
Prior allogeneic stem cell transplantation within 5 years of FL diagnosis
Lab requirements
Blood counts
Platelet count ≥75 x 10^9/L without transfusion within 14 days prior to first dose; ANC ≥1 x 10^9/L; Hemoglobin level ≥9 g/dL without transfusion within 14 days prior to first dose. Patients who do not meet criteria for bone marrow function due to marrow involvement of lymphoma and/or other disease-related cytopenias may be enrolled after discussion with, and confirmation by the PI.
Kidney function
Serum creatinine ≤ULN or estimated creatinine clearance ≥ 45 mL/min by Cockcroft-Gault method or other institutional standard methods
Liver function
AST and ALT levels ≤3 x ULN; total bilirubin level ≤1.5 x ULN (except with documented history of Gilbert syndrome)
Adequate hepatic function as follows: aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤3 x upper limit of normal (ULN); total bilirubin level ≤1.5 x ULN (except with documented history of Gilbert syndrome) Adequate bone marrow function as follows: Platelet count ≥75 x 10^9/L without transfusion within 14 days prior to first dose of mosunetuzumab; ANC ≥1 x 10^9/L; Hemoglobin level ≥9 g/dL without transfusion within 14 days prior to the first dose of mosunetuzumab Serum creatinine ≤ULN or estimated creatinine clearance ≥ 45 mL/min by Cockcroft-Gault method or other institutional standard methods
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgetown University (Data Collection Only) · Washington D.C., District of Columbia
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities · Basking Ridge, New Jersey
- Hackensack Meridian Health (Data collection only) · Hackensack, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify